BC Extra | Jan 6, 2017
Company News

Judge orders ban on Praluent sales

A federal judge granted Amgen Inc. (NASDAQ:AMGN) a permanent injunction banning U.S. sales of rival cholesterol-lowering drug Praluent alirocumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY), citing irreparable harm due to infringement of...
BioCentury | Sep 5, 2016
Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BC Week In Review | Jun 1, 2015
Company News

Roche, Galenica deal

Roche granted Galenica exclusive, U.S. commercialization rights to Mircera methoxy polyethylene glycol-epoetin beta. Roche will manufacture and supply Mircera to Galenica. Roche will receive an upfront payment and supply reimbursements and is eligible for milestones...
BC Extra | May 29, 2015
Company News

Roche grants Galenica U.S. rights to Mircera

Galenica Ltd. (SIX:GALN) gained exclusive U.S. commercialization rights to Mircera methoxy polyethylene glycol-epoetin beta from Roche (SIX:ROG; OTCQX:RHHBY). Roche will manufacture and supply the drug to Galenica. Financial terms were undisclosed. Mircera was approved in...
BC Week In Review | Jul 30, 2012
Clinical News

Mircera methoxy polyethylene glycol-epoetin beta regulatory update

Roche has rights to Tamiflu, a neuraminidase (NEU1; SIAL1) inhibitor, from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Xeloda is an oral prodrug form of 5-fluorouracil (5-FU). Pegasys is pegylated recombinant interferon (IFN) alfa-2a. Mircera...
BC Week In Review | Mar 5, 2012
Company News

Nektar, Royalty Pharma sales and marketing update

Nektar agreed to sell its royalty rights to anemia drug Mircera methoxy polyethylene glycol-epoetin beta and autoimmune drug Cimzia certolizumab pegol to Royalty Pharma for $124 million. Nektar said it will use the money to...
BioCentury | Mar 5, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) jumped $1.63 (71%) to $3.94 on Tuesday, while partner pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.27 (13%) to $2.42, after the U.K. and six other EU member states reached an...
BC Extra | Mar 1, 2012
Company News

Nektar sells Cimzia, Mircera royalties

Nektar Therapeutics (NASDAQ:NKTR) agreed to sell its royalty rights to anemia drug Mircera methoxy polyethylene glycol-epoetin beta and autoimmune drug Cimzia certolizumab pegol to Royalty Pharma (New York, N.Y.) for $124 million. Nektar said it...
BC Week In Review | Feb 6, 2012
Company News

Roche sales and marketing update

Roche stopped releasing Mircera methoxy polyethylene glycol-epoetin beta and Xenical orlistat after finding GMP deficiencies at its Florence, S.C., manufacturing facility. Roche said it agreed with U.S. and European health authorities to continue releasing other...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
Items per page:
1 - 10 of 119